Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-521

As we all know, we are in uncharted waters on so many fronts with this modern pandemic, and times are becoming increasingly desperate in some places, especially the USA. Yes, we are seeing curve flattening in many countries, and even though we may have seen the worse in some, many countries are far from peaking. The USA is probably one of these.

This frightening dynamic is going to push human thought and responses in new directions. What I'm trying to say is this: A controlled new study will begin now, just as the one in Spain is, but these times will bring MSB's treatment to the forefront of all treatments. With every patient coming off a ventilator, the pressure will mount to provide MSV to others, immediately.

In short, any further success will quickly become a first line treatment. With every successful case, the book will be one patient closer to being thrown out the window.

That's my view.